This recombinant toxin slows fast inactivation on Nav1.1/SCN1A (EC(50)=17 nM), Nav1.4/SN4A (EC(50)=7.5 nM), Nav1.5/SCN5A (EC(50)=9.2 nM) and Nav1.6/SCN8A (EC(50)=37.3 nM) voltage-gated sodium channels (PubMed:32259093). On Nav1.1/SCN1A channel, it acts as an agonist by inducing a shift in both the voltage dependence of channel inactivation (alpha-toxin activity) and activation (beta-toxin activity) (PubMed:32259093). In vivo, shows moderate insecticidal activities (PubMed:32259093). It induces irreversible paralysis in blowflies and lethal effects in D.melanogaster (PubMed:32259093). Expressed by the venom gland. Has the structural arrangement of an alpha-helix connected to antiparallel beta-sheets by disulfide bonds (CS-alpha/beta). Monoisotopic mass. LD(50) of the recombinant toxin is 745 +- 108 pmol/g on D.melanogaster. LD(50) of the native toxin is 914 +- 138 pmol/g on D.melanogaster. Lead molecule for the development of selective Nav1.1/SCN1A agonists for the treatment of Dravet syndrome epilepsy. Shows very weak activity on Nav1.2/SCN2A, Nav1.3/SCN3A, and Nav1.7/SCN9A voltage-gated sodium channels. The complete amino acid sequence was obtained by combining proteomic and transcriptomic techniques. Belongs to the long (4 C-C) scorpion toxin superfamily. Sodium channel inhibitor family. Alpha subfamily.